Form 13-F position report

ADICET BIO INC

Reported by D E Shaw & Co Inc

ACET CUSIP 007002108 Manager CIK 0001009207

Reported 244,873 shares, up 213,419 (678.5%) from the prior quarter.

Reported value 338.9%; share count 678.5% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q3 2023
Shares 244,873 Quarter-end amount reported
Reported value $335,476 Fair value at quarter end
Consecutive quarters held 13 Through Q3 2023

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 3716000
2022-03-31 4416000
2022-06-30 4844000
2022-09-30 1598000
2022-12-31 0
2023-03-31 256925
2023-06-30 76433
2023-09-30 335476
2023-12-31 655110
2024-03-31 765980
2024-06-30 1011606
2024-09-30 1320580
2024-12-31 814876
2025-03-31 381629
2025-06-30 13541
2025-09-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

16 quarters
Quarterly reported position history for ADICET BIO INC held by D E Shaw & Co Inc.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2025 Reduced 0 -22,199 (-100.0%) 0 $0 2025-11-14
Q2 2025 Reduced 22,199 -483,270 (-95.6%) < 0.01% $13,541 2025-08-14
Q1 2025 Reduced 505,469 -341,595 (-40.3%) < 0.01% $381,629 2025-05-15
Q4 2024 Reduced 847,064 -70,006 (-7.6%) < 0.01% $814,876 2025-02-14
Q3 2024 Added 917,070 +81,032 (9.7%) < 0.01% $1,320,580 2024-11-14
Q2 2024 Added 836,038 +510,089 (156.5%) < 0.01% $1,011,606 2024-08-14
Q1 2024 Reduced 325,949 -20,670 (-6.0%) < 0.01% $765,980 2024-05-15
Q4 2023 Added 346,619 +101,746 (41.6%) < 0.01% $655,110 2024-02-14
Q3 2023 Added 244,873 +213,419 (678.5%) < 0.01% $335,476 2023-11-14
Q2 2023 Reduced 31,454 -13,151 (-29.5%) < 0.01% $76,433 2023-08-14
Q1 2023 New 44,605 +44,605 (0.0%) < 0.01% $256,925 2023-05-15
Q4 2022 Reduced 0 -112,355 (-100.0%) 0 $0 2023-02-14
Q3 2022 Reduced 112,355 -219,457 (-66.1%) < 0.01% $1,598,000 2022-11-14
Q2 2022 Added 331,812 +110,685 (50.1%) < 0.01% $4,844,000 2022-08-15
Q1 2022 Added 221,127 +8,670 (4.1%) < 0.01% $4,416,000 2022-05-16
Q4 2021 Added 212,457 +168,586 (384.3%) < 0.01% $3,716,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

108 managers reported ADICET BIO INC for Q3 2023.

Managers reporting ADICET BIO INC in Q3 2023.
Manager Activity Shares Change % of reported 13F Reported value Tenure
ORBIMED ADVISORS LLC Unchanged 8,322,140 0 0.24% $11,401,332 13 qtrs
RTW INVESTMENTS LP Unchanged 4,241,472 0 0.12% $5,810,817 8 qtrs
MORGAN STANLEY Added 3,836,377 +1,388,534 < 0.01% $5,255,836 13 qtrs
COWEN AND COMPANY LLC Reduced 2,715,278 -119,586 0.26% $3,719,930 7 qtrs
BlackRock Inc Reduced 2,269,478 -118,234 < 0.01% $3,109,184 13 qtrs
Carlyle Group Inc Unchanged 2,115,385 0 0.12% $2,876,924 3 qtrs
VANGUARD GROUP INC Added 1,672,386 +3,700 < 0.01% $2,291,169 13 qtrs
TANG CAPITAL MANAGEMENT LLC Reduced 1,226,352 -1,253,200 0.24% $1,680,102 4 qtrs
MILLENNIUM MANAGEMENT LLC Added 893,882 +114,203 < 0.01% $1,224,618 6 qtrs
DAFNA Capital Management LLC Unchanged 797,054 0 0.34% $1,091,964 13 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2023
Filed
November 14, 2023
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
244,873
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.